期刊
JOURNAL OF IMMUNOTHERAPY
卷 28, 期 6, 页码 593-598出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.cji.0000178913.41256.06
关键词
anti-CTLA-4 antibody; autoimmunity; autoimmune hypophysitis; melanoma; renal cell cancer; immunotherapy
资金
- Intramural NIH HHS [Z01 SC003811-32] Funding Source: Medline
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4(+)CD25(+) T cells. In patients with advanced melanoma, Our Group reported that administration of anti-CTLA-4 antibody mediated objective cancer regression in 13% of patients. This study also established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis. Since this initial report, 7 additional patients with anti-CTLA-4 antibody-induced autoimmune hypophysitis have been accumulated. The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据